Healthy Accents Nighttime Cold And Flu

Healthy Accents Nighttime Cold And Flu Manufacturers

• Dza Brands Llc
  

  ×

  Healthy Accents Nighttime Cold And Flu | Dza Brands Llc

  

  ---

  take only as recommended – see Liver warning use dose cup do not exceed 4 doses per 24 hours adults and children 12 years and over 30 mL (2 TBSP) every 6 hours children 4 to under 12 years ask a doctor children under 4 years do not use when using other Daytime or Nighttime products, carefully read each label to insure correct dosing

  Close
  No Recall

  More Info
• Dza Brands Llc
  

  ×

  Healthy Accents Nighttime Cold And Flu | Dza Brands Llc

  

  ---

  take only as recommended – see Liver warning use dose cup do not exceed 4 doses per 24 hours adults and children 12 years and over 30 mL (2 TBSP) every 6 hours children 4 to under 12 years ask a doctor children under 4 years do not use when using other Daytime or Nighttime products, carefully read each label to insure correct dosing

  Close
  No Recall

  More Info
• Dza Brands Llc
  

  ×

  Healthy Accents Nighttime Cold And Flu | Dza Brands Llc

  

  ---

  • take only as directed - see Overdose warning • use dose cup • do not exceed 4 doses per 24 hrs

  adults & children 12 yrs & over

  30 mL (2 TBSP) every 6 hrs

  children 4 to under 12 yrs

  ask a doctor

  children under 4 yrs

  do not use

  Close
  No Recall

  More Info
• Dza Brands Llc
  

  ×

  Healthy Accents Nighttime Cold And Flu | Dza Brands Llc

  

  ---

  • take only as directed – see overdose warning • do not exceed 4 doses per 24 hours

  adults & children 12 yrs & over

  2 softgels with water every 6 hrs

  children 4 to under 12 yrs

  ask a doctor

  children under 4 yrs

  do not use

  Close
  No Recall

  More Info
• Dza Brands Llc
  

  ×

  Healthy Accents Nighttime Cold And Flu | Hy-vee, Inc.

  

  ---

  Do not use more unless directed by a doctor. See Warnings.

  adults & children

  12 years and over

  one bottle once daily

  children 2 to under

  12 years

  1/2 bottle once daily

  Discard unused portion

  children under

  2 years

  do not use

  CAUTION:

  Remove green protective shield before inserting. Hold bottle upright, grasping bottle cap with fingers. Grasp protective shield with other hand and pull gently to remove.

  Positioning:

  Left-side position: lie on left side with knee bent and arms at rest.

  Knee-chest position: kneel, then lower head and chest forward until left side of face is resting on surface. Position arms comfortably.

  Administering enema:

  • with steady pressure, gently insert enema with tip pointing toward navel. • squeeze bottle until recommended dose is expelled (it is not necessary to empty unit completely. Bottle contains more liquid than needed for effective use. A small amount of liquid will remain in bottle after squeezing). • remove tip from rectum • stop using if tip is hard to insert. Forcing the tip into the rectum can cause injury (especially if you have hemorrhoids). If enema tip causes rectal bleeding or pain, get immediate medical care. • maintain position until urge to evacuate is strong (usually 1 to 5 minutes) • if no urge is felt after 5 minutes of using, try to empty bowel. Call a doctor promptly if no liquid comes out of the rectum after 30 minutes because dehydration could occur.

  Close
  No Recall

  More Info
• Dza Brands Llc
  

  ×

  Healthy Accents Nighttime Cold And Flu | Sun Pharmaceutical Industries Limited

  

  ---

  All dosing should be given in a twice-a-day regimen. Oxcarbazepine oral suspension and oxcarbazepine film-coated tablets may be interchanged at equal doses.
  
  Oxcarbazepine tablets should be kept out of the reach and sight of children.
  
  Oxcarbazepine tablets can be taken with or without food [see Clinical Pharmacology (12.3)].

  2.1 Adjunctive Therapy for Adults

  Treatment with oxcarbazepine should be initiated with a dose of 600 mg/day, given in a twice-a-day regimen. If clinically indicated, the dose may be increased by a maximum of 600 mg/day at approximately weekly intervals; the recommended daily dose is 1,200 mg/day. Daily doses above 1,200 mg/day show somewhat greater effectiveness in controlled trials, but most patients were not able to tolerate the 2,400 mg/day dose, primarily because of CNS effects. It is recommended that the patient be observed closely and plasma levels of the concomitant AEDs be monitored during the period of oxcarbazepine titration, as these plasma levels may be altered, especially at oxcarbazepine doses greater than 1,200 mg/day [see Drug Interactions (7.1)].

  2.2 Conversion to Monotherapy for Adults

  Patients receiving concomitant AEDs may be converted to monotherapy by initiating treatment with oxcarbazepine at 600 mg/day (given in a twice-a-day regimen) while simultaneously initiating the reduction of the dose of the concomitant AEDs. The concomitant AEDs should be completely withdrawn over 3 to 6 weeks, while the maximum dose of oxcarbazepine should be reached in about 2 to 4 weeks. Oxcarbazepine may be increased as clinically indicated by a maximum increment of 600 mg/day at approximately weekly intervals to achieve the recommended daily dose of 2,400 mg/day. A daily dose of 1,200 mg/day has been shown in one study to be effective in patients in whom monotherapy has been initiated with oxcarbazepine. Patients should be observed closely during this transition phase.

  2.3 Initiation of Monotherapy for Adults

  Patients not currently being treated with AEDs may have monotherapy initiated with oxcarbazepine. In these patients, oxcarbazepine should be initiated at a dose of 600 mg/day (given in a twice-a-day regimen); the dose should be increased by 300 mg/day every third day to a dose of 1,200 mg/day. Controlled trials in these patients examined the effectiveness of a 1,200 mg/day dose; a dose of 2,400 mg/day has been shown to be effective in patients converted from other AEDs to oxcarbazepine monotherapy (see above).

  2.4 Adjunctive Therapy for Pediatric Patients (Aged 2 to 16 Years)

  In pediatric patients aged 4 to 16 years, treatment should be initiated at a daily dose of 8 to 10 mg/kg generally not to exceed 600 mg/day, given in a twice-a-day regimen. The target maintenance dose of oxcarbazepine should be achieved over two weeks, and is dependent upon patient weight, according to the following chart:
  20 to 29 kg - 900 mg/day
  29.1 to 39 kg - 1,200 mg/day
  >39 kg - 1,800 mg/day
  In the clinical trial, in which the intention was to reach these target doses, the median daily dose was 31 mg/kg with a range of 6 to 51 mg/kg.
  
  In pediatric patients aged 2 to <4 years, treatment should also be initiated at a daily dose of 8 to 10 mg/kg generally not to exceed 600 mg/day, given in a twice-a-day regimen. For patients under 20 kg, a starting dose of 16 to 20 mg/kg may be considered [see Clinical Pharmacology (12.3)]. The maximum maintenance dose of oxcarbazepine should be achieved over 2 to ­4 weeks and should not exceed 60 mg/kg/day in a twice-a-day regimen.
  
  In the clinical trial in pediatric patients (2 to 4 years of age) in which the intention was to reach the target dose of 60 mg/kg/day, 50% of patients reached a final dose of at least 55 mg/kg/day.
  
  Under adjunctive therapy (with and without enzyme-inducing AEDs), when normalized by body weight, apparent clearance (L/hr/kg) decreased when age increased such that children 2 to <4 years of age may require up to twice the oxcarbazepine dose per body weight compared to adults; and children 4 to ≤12 years of age may require a 50% higher oxcarbazepine dose per body weight compared to adults.

  2.5 Conversion to Monotherapy for Pediatric Patients (Aged 4 to 16 Years)

  Patients receiving concomitant antiepileptic drugs may be converted to monotherapy by initiating treatment with oxcarbazepine at approximately 8 to 10 mg/kg/day given in a twice-a-day regimen, while simultaneously initiating the reduction of the dose of the concomitant antiepileptic drugs. The concomitant antiepileptic drugs can be completely withdrawn over 3 to 6 weeks while oxcarbazepine may be increased as clinically indicated by a maximum increment of 10 mg/kg/day at approximately weekly intervals to achieve the recommended daily dose. Patients should be observed closely during this transition phase.
  
  The recommended total daily dose of oxcarbazepine is shown in the table below.

  2.6 Initiation of Monotherapy for Pediatric Patients (Aged 4 to 16 Years)

  Patients not currently being treated with antiepileptic drugs may have monotherapy initiated with oxcarbazepine. In these patients, oxcarbazepine should be initiated at a dose of 8 to 10 mg/kg/day given in a twice-a-day regimen. The dose should be increased by 5 mg/kg/day every third day to the recommended daily dose shown in the table below.

  
  Table 1: Range of Maintenance Doses of Oxcarbazepine for Children by Weight During Monotherapy Weight in kg
  From
  To
  Dose (mg/day)
  Dose (mg/day)
  20
  600
  900
  25
  900
  1,200
  30
  900
  1,200
  35
  900
  1,500
  40
  900
  1,500
  45
  1,200
  1,500
  50
  1,200
  1,800
  55
  1,200
  1,800
  60
  1,200
  2,100
  65
  1,200
  2,100
  70
  1,500
  2,100
  
  
  2.7 Patients with Hepatic Impairment

  In general, dose adjustments are not required in patients with mild-to-moderate hepatic impairment [see Clinical Pharmacology (12.3).]

  2.8 Patients with Renal Impairment

  In patients with impaired renal function (creatinine clearance <30 mL/min) oxcarbazepine therapy should be initiated at one-half the usual starting dose (300 mg/day) and increased slowly to achieve the desired clinical response [see Clinical Pharmacology (12.3)]

  Close
  No Recall

  More Info